Founded in January 2024, Toleris Biotherapeutics is a pioneering biotech company based in Würzburg, Germany. Led by an experienced team of scientists and entrepreneurs, we specialize in developing first-in-class AutoImmunity Modifying Biologics (AIM Bios) - a breakthrough therapeutic approach that harnesses the body’s natural tolerance mechanism during pregnancy to treat autoimmune diseases.
Toleris holds a global license for the AIM Bio therapeutics platform across all disease areas, except for NMOSD and Parkinson’s disease, for which we have the first right of refusal.
We are actively seeking investors and strategic partners to help unlock the full potential of our award-winning platform technology. If you’re interested in shaping the future of autoimmune disease treatment, we’d love to connect.